A vaccinia virus renaissance: New vaccine and immunotherapeutic uses after smallpox eradication

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 7, 2012, Pages 961-970

  Verardi, Paulo H ^a   Titong, Allison ^a   Hagen, Caitlin J ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Cancer immunotherapy; Oncolytic cancer therapy; Smallpox; Vaccines; Vaccinia virus; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ANTHRAX VACCINE; BCG VACCINE; CANCER VACCINE; CV 301; DNA VACCINE; DOCETAXEL; DOUBLE STRANDED DNA; ELSTREE BN; EM 63; GL ONC 1; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; JX 594; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; RABIES VACCINE; RABORAL V RG; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SMALLPOX VACCINE; TG 4010; UNCLASSIFIED DRUG; VIRUS VECTOR; DRUG CARRIER; VIRUS VACCINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNIZATION; CANINE DISTEMPER; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; COLORECTAL CANCER; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ERADICATION THERAPY; HEAD AND NECK CANCER; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; INFLUENZA; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LUNG CARCINOMA; MALAISE; MALARIA; MELANOMA; NEWCASTLE DISEASE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PERITONEUM CANCER; PESTE DES PETITS RUMINANTS; PROSTATE CANCER; RABIES; REVIEW; RIFT VALLEY FEVER; RINDERPEST; SMALLPOX; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THERMOSTABILITY; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UTERINE TUBE TUMOR; VACCINATION; VACCINE PRODUCTION; VACCINIA VIRUS; VESICULAR STOMATITIS; VIRUS CELL INTERACTION; VIRUS ENCEPHALITIS; VIRUS GENOME; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS REPLICATION; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOST RANGE; IMMUNOLOGY; PHYSIOLOGY;

DRUG CARRIERS; GENETIC VECTORS; HOST SPECIFICITY; HUMANS; ONCOLYTIC VIRUSES; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84864037212     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21080     Document Type: Review

References (94)

1. Wehrle PF. A reality in our time - certification of the global eradication of smallpox. J Infect Dis 1980; 142:636-8; PMID:7003037; http://dx.doi.org/10.1093/infdis/142.4.636.
2. Fenner F, Henderson DA, Arita I, Jeek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: World Health Organization 1988.
3. Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, Eds. Fields' virology. Philadelphia: Lippincott Williams & Wilkins 2007; 2906-45.
4. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303-9; PMID:4396189; http://dx.doi.org/10.1093/infdis/122.4.303.
5. Lane JM, Goldstein J. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med 2003; 138:488-93; PMID:12639083.
6. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002; 5:84-90; PMID:11990216.
7. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005; 79:7845-51; PMID:15919938; http://dx.doi.org/10.1128/JVI.79.12.7845-51.2005.
8. Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005; 365:398-409; PMID:15680454.
9. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 2003; 9:1125-30; PMID:12925845; http://dx.doi.org/10.1038/nm916.
10. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int J Infect Dis 2004; 8:31-44; PMID:15491873.
11. Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009; 27:1637-44; PMID:19071184; http://dx.doi.org/10.1016/j.vaccine.2008.11.079.
12. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008; 17:555-64; PMID:18363519; http://dx.doi.org/10.1517/13543784.17.4.555.
13. Mayr A, Stickl H, Müller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol B 1978; 167:375-90; PMID:219640.
14. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79:347-52; PMID:9472619.
15. Hochstein-Mintzel V, Hänichen T, Huber HC, Stickl H. An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl). Zentralbl Bakteriol Orig A 1975; 230:283-97; PMID:1146441.
16. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006; 24:2065-70; PMID:16337719; http://dx.doi.org/10.1016/j.vaccine.2005.11.022.
17. von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010; 28:1209-16; PMID:19944151; http://dx.doi.org/10.1016/j. vaccine. 2009.11.030.
18. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188:217-32; PMID:1566575; http://dx.doi.org/10.1016/0042-6822(92)90752-B.
19. Paoletti E, Tartaglia J, Taylor J. Safe and effective pox-virus vectors - NYVAC and ALVAC. Dev Biol Stand 1994; 82:65-9; PMID:7958484.
20. Midgley CM, Putz MM, Weber JN, Smith GL. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol 2008; 89:2992-7; PMID:19008384; http://dx.doi.org/10.1099/vir.0.2008/004440-0.
21. Hashizume S, Yoshizawa H, Morita M, Suzuki K. Properties of attenuated mutant of vaccinia virus, LC16M8, derived from Lister strain. In: Quinnan GV, Ed. Vaccinia viruses as vectors for vaccine antigens Proceedings of the Workshop on Vaccinia Viruses as Vectors for Vaccine Antigens. New York NY: Elsevier 1985; 87-99.
22. Saito T, Fujii T, Kanatani Y, Saijo M, Morikawa S, Yokote H, et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009; 301:1025-33; PMID:19278946; http:// dx.doi.org/10.1001/jama.2009.289.
23. Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis 2011; 204:1395-402; PMID:21921208; http://dx.doi.org/10.1093/infdis/jir527.
24. Takahashi-Nishimaki F, Funahashi S, Miki K, Hashizume S, Sugimoto M. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology 1991; 181:158-64; PMID:1994573; http://dx.doi.org/10.1016/0042-6822(91)90480-Y.
25. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006; 24:7009-22; PMID:17052815; http://dx.doi.org/10. 1016/j.vaccine.2006.03.087.
26. Johnson BF, Kanatani Y, Fujii T, Saito T, Yokote H, Smith GL. Serological responses in humans to the smallpox vaccine LC16m8. J Gen Virol 2011; 92:2405-10; PMID:21715598; http://dx.doi.org/10.1099/vir.0.034207-0.
27. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 2003; 306:181-95; PMID:12620810; http://dx.doi.org/10.1016/S0042-6822(02)00038-7.
28. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 2008; 371:98-107; PMID:17950773; http://dx.doi.org/10.1016/j. virol.2007.09.029.
29. Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 2004; 22:3358-66; PMID:15308360; http://dx.doi.org/10.1016/j.vaccine. 2004.02.034.
30. Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2011; 203:95-102; PMID:21148501; http://dx.doi.org/10. 1093/infdis/jiq017.
31. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004; 78:10230-7; PMID:15367588; http://dx.doi.org/10.1128/JVI.78.19.10230-7. 2004.
32. Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005; 79:11724-33; PMID:16140750; http://dx.doi.org/10.1128/JVI.79.18.11724-33. 2005.
33. Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, et al. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 2010; 28:6627-36; PMID:20659519; http://dx.doi.org/10.1016/j.vaccine.2010.07.030.
34. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, et al. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011; 29:501-11; PMID:21055490; http://dx.doi.org/10.1016/j.vaccine. 2010.10.064.
35. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc Natl Acad Sci USA 1996; 93:11341-8; PMID:8876137; http://dx.doi.org/10.1073/pnas.93.21.11341.
36. Yilma T. Applications of recombinant vaccinia virus for veterinary vaccines. Dev Biol Stand 1994; 82:201-9; PMID:7958475.
37. Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 1984; 81:7194-8; PMID:6095272; http://dx.doi.org/10.1073/pnas.81.22.7194.
38. Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984; 312:163-6; PMID:6548799; http://dx.doi.org/10.1038/312163a0.
39. Pastoret PP, Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol Infect 1996; 116:235-40; PMID:8666066; http://dx.doi.org/10.1017/S0950268800052535.
40. Giavedoni L, Jones L, Mebus C, Yilma T. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci USA 1991; 88:8011-5; PMID:1896447; http://dx.doi.org/10.1073/pnas.88.18.8011.
41. Verardi PH, Aziz FH, Ahmad S, Jones LA, Beyene B, Ngotho RN, et al. Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins. J Virol 2002; 76:484-91; PMID:11752138; http://dx.doi.org/10.1128/ JVI.76.2.484-91.2002.
42. Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite preexisting vaccinia immunity. Vaccine 2009; 27:4468-74; PMID:19450644; http://dx.doi.org/10.1016/j.vaccine. 2009.05.018.
43. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.; MOPHTAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492.
44. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012; 7:31208; PMID:22363582; http://dx.doi.org/10.1371/journal.pone.0031208.
45. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011; 19:2269-76; PMID:21862998; http://dx.doi.org/10.1038/mt.2011.176.
46. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012; 205:772-81; PMID:22275401; http://dx.doi.org/10.1093/infdis/jir850.
47. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010; 40:279-90; PMID:20017188; http://dx.doi.org/10.1002/eji. 200939754.
48. Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol 2008; 82:10896-905; PMID:18753204; http://dx.doi.org/10.1128/JVI.01179-08.
49. de Waal L, Wyatt LS, Yüksel S, van Amerongen G, Moss B, Niesters HG, et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 2004; 22:923-6; PMID:15161069; http://dx.doi.org/10.1016/j.vaccine.2003.10.010.
50. Merkel TJ, Perera PY, Kelly VK, Verma A, Llewellyn ZN, Waldmann TA, et al. Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. Proc Natl Acad Sci USA 2010; 107:18091-6; PMID:20921397; http://dx.doi.org/10.1073/pnas.1013083107.
51. Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 2004; 78:834-40; PMID:14694115; http://dx.doi.org/10. 1128/JVI.78.2.834-40.2004.
52. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi.org/10. 1007/s00262-009-0782-8.
53. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597.
54. National Library of Medicine (US). ClinicalTrials.gov [Internet]. Bethesda (MD) 2000 (accessed 2012 June 1).
55. Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR, et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res 2011; 71:5235-44; PMID:21670078; http://dx.doi.org/10.1158/0008-5472.CAN-10-4076.
56. Mandl SJ, Rountree RB, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, et al. Immunotherapy with MVABN® -HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunol Immunother 2012; 61:19-29; PMID:21822917; http://dx.doi.org/10.1007/ s00262-011-1077-4.
57. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008; 57:977-86; PMID:18060404; http://dx.doi.org/10.1007/s00262-007-0428-7.
58. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 2009; 7:2; PMID:19128501; http://dx.doi.org/10.1186/1479-5876-7-2.
59. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010; 16:5539-47; PMID:20881001; http://dx.doi.org/10.1158/1078-0432.CCR-10-2082.
60. Harrop R, Shingler W, Kelleher M, de Belin J, Treasure P. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal and prostate cancer patients. J Immunother 2010; 33:999-1005; PMID:20948436; http://dx.doi.org/10.1097/CJI. 0b013e3181f5dac7.
61. Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother 2011; 60:829-37; PMID:21387109; http://dx.doi. org/10.1007/s00262-011-0993-7.
62. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012; 109:5797-802; PMID:22454499; http://dx.doi.org/10.1073/pnas. 1117208109.
63. Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009; 27:379-86; PMID:18931824; http://dx.doi.org/10.1007/s10637-008-9187-3.
64. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12:1125-33; PMID:22019520; http://dx.doi.org/10.1016/S1470-2045(11)70259-5.
65. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17:7164-73; PMID:22068656; http://dx.doi.org/10.1158/1078-0432.CCR-11-0649.
66. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9:64-71; PMID:19104515; http://dx.doi.org/10.1038/nrc2545.
67. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61:8751-7; PMID:11751395.
68. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7:66-73; PMID:10678358; http://dx.doi.org/10.1038/sj.cgt.7700075.
69. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16:1637-42; PMID:18628758; http://dx.doi.org/10.1038/mt.2008.143.
70. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9:533-42; PMID:18495536; http://dx.doi.org/10.1016/S1470-2045(08)70107-4.
71. Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011; 19:1913-22; PMID:21772252; http://dx.doi.org/10.1038/mt.2011.132.
72. McCart JA, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 2004; 10:553-61; PMID:15336655; http://dx.doi.org/10.1016/j.ymthe.2004.06.158.
73. Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, Gorry MC, et al. Oncolytic virotherapy for ovarian carcinomatosis using a replicationselective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 2008; 15:115-25; PMID:18084242; http://dx.doi.org/10.1038/sj. cgt.7701110.
74. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007; 67:10038-46; PMID:17942938; http://dx.doi.org/10.1158/0008-5472.CAN-07-0146.
75. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 2012; 7:37239; PMID:22615950; http://dx.doi.org/ 10.1371/journal.pone.0037239.
76. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1 h68. Mol Cancer Ther 2009; 8:141-51; PMID:19139123; http://dx.doi.org/10.1158/1535-7163.MCT-08-0533.
77. Yu YA, Timiryasova T, Zhang Q, Beltz R, Szalay AA. Optical imaging: bacteria, viruses and mammalian cells encoding light-emitting proteins reveal the locations of primary tumors and metastases in animals. Anal Bioanal Chem 2003; 377:964-72; PMID:12879198; http://dx.doi.org/10.1007/s00216-003-2065-0.
78. Plotke F, Lazowski ES. Comparative Results of Smallpox Revaccination Using Regular and Dry Smallpox Vaccine (Dryvax). IMJ Ill Med J 1964; 125:140-1; PMID:14121126.
79. Jones L, Giavedoni L, Saliki JT, Brown C, Mebus C, Yilma T. Protection of goats against peste des petits ruminants with a vaccinia virus double recombinant expressing the F and H genes of rinderpest virus. Vaccine 1993; 11:961-4; PMID:8212844; http://dx.doi.org/10.1016/0264-410X(93)90386-C.
80. Mackett M, Yilma T, Rose JK, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 1985; 227:433-5; PMID:2981435; http://dx.doi.org/10.1126/science.2981435.
81. Meulemans G, Letellier C, Gonze M, Carlier MC, Burny A. Newcastle disease virus F glycoprotein expressed from a recombinant vaccinia virus vector protects chickens against live-virus challenge. Avian Pathol 1988; 17:821-7; PMID:18766743; http://dx.doi.org/10.1080/03079458808436504.
82. Espion D, de Henau S, Letellier C, Wemers CD, Brasseur R, Young JF, et al. Expression at the cell surface of native fusion protein of the Newcastle disease virus (NDV) strain Italien from cloned cDNA. Arch Virol 1987; 95:79-95; PMID:3592986; http://dx.doi.org/10.1007/BF01311336.
83. Carson C, Antoniou M, Ruiz-Argüello MB, Alcami A, Christodoulou V, Messaritakis I, et al. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 2009; 27:1080-6; PMID:19095029; http://dx.doi.org/10.1016/j.vaccine. 2008.11.094.
84. Taylor J, Pincus S, Tartaglia J, Richardson C, Alkhatib G, Briedis D, et al. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol 1991; 65:4263-74; PMID:1830113.
85. Cross ML, Fleming SB, Cowan PE, Scobie S, Whelan E, Prada D, et al. Vaccinia virus as a vaccine delivery system for marsupial wildlife. Vaccine 2011; 29:4537-43; PMID:21570435; http://dx.doi.org/10.1016/j.vaccine. 2011.04.093.
86. Papin JF, Verardi PH, Jones LA, Monge-Navarro F, Brault AC, Holbrook MR, et al. Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci USA 2011; 108:14926-31; PMID:21873194; http://dx.doi.org/10.1073/pnas. 1112149108.
87. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011; 29:8417-28; PMID:21864626; http://dx.doi.org/10.1016/j.vaccine. 2011.08.001.
88. Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, et al.; EuroVacc Consortium. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 2008; 26:3153-61; PMID:18502002; http://dx.doi.org/10.1016/ j.vaccine.2008.03.083.
89. McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008; 26:3162-74; PMID:18502003; http://dx.doi.org/10.1016/j.vaccine.2008.02.072.
90. Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, poly-functional and long-lasting T cell responses. J Exp Med 2008; 205:63-77; PMID:18195071; http://dx.doi.org/10.1084/jem.20071331.
91. García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 2011; 29:8309-16; PMID:21907749; http://dx.doi.org/10.1016/j.vaccine. 2011.08.098.
92. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610-9; PMID:21282192; http://dx.doi.org/10.1093/infdis/ jiq105.
93. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52:1-7; PMID:21148512; http://dx.doi.org/10.1093/cid/ciq015.
94. Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One 2011; 6:14626; PMID:21347224; http://dx.doi.org/10.1371/journal.pone.0014626.